It’s launching their physicians into uncharted territory. Corner-store cannabidiol “scares the bejesus” out of Dr. Jacqueline French. French, a neurologist, tries to steer her patients away from sprinting to the neighborhood bodega to buy versions of the hemp derivative that’s better known as CBD

Quick Read

Congress wants a single ALS patient to get a therapy never tested in humans. A family in Iowa believes the Food and Drug Administration will decide whether their only surviving daughter lives or dies, and they’ve been on a monthslong crusade to break through its bureaucracy. And they’re succeeding

Quick Read

Cancer drugs that speed onto the market based on encouraging preliminary studies often don’t show clear benefits when more careful follow-up trials are done, according to research published Tuesday

Quick Read

Some biotech companies are offering a new way to soften the shock of drug prices: Insurers pay only if the patient improves

Quick Read

Overprescribed

April 3, 2019

High cost isn’t America’s only drug problem. The pharmaceutical industry has followed a brilliant two-pronged strategy to maximize its profits: raise prices and increase consumption of medications

Quick Read

The operation is a daring one: To replace a failing heart valve, cardiologists insert a replacement through a patient’s groin and thread it all the way to the heart, maneuvering it into the site of the old valve

Quick Read

One of the namesakes of the federal “right-to-try” law confirmed Tuesday that he gained access to an experimental treatment thanks to the new law

Quick Read

But that can hurt you. Few people are familiar with the term “step therapy,” but most Americans have health insurance policies that adopt it. Step therapy programs, also known as “fail first policies,” require patients to try less expensive treatments before insurers agree to pay for more costly alternatives

Quick Read